Paula Ghaneh
A5020254111- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal disorders and treatments
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Liver Disease Diagnosis and Treatment
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Gastrointestinal Tumor Research and Treatment
- Virus-based gene therapy research
- Epigenetics and DNA Methylation
- Colorectal Cancer Screening and Detection
- Pediatric Hepatobiliary Diseases and Treatments
- Peptidase Inhibition and Analysis
- Metabolism, Diabetes, and Cancer
- Genetic factors in colorectal cancer
Royal Liverpool University Hospital
2014-2025
University of Liverpool
2016-2025
Musgrove Park Hospital
2023
Aintree University Hospitals NHS Foundation Trust
2021-2022
Cancer Research UK
2007-2020
Royal Liverpool and Broadgreen University Hospital NHS Trust
2010-2019
Faculdade de Agudos
2017
NIHR Liverpool Pancreatic Biomedical Research Unit
2012-2016
Aintree University Hospital
2007-2016
Directorate of Health
2016
BackgroundThe ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better tumour response capecitabine alone advanced or metastatic We aimed determine efficacy safety compared monotherapy for cancer.MethodsWe did a phase 3, two-group, open-label, multicentre, randomised at 92 hospitals England, Scotland, Wales,...
Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known the most effective agent in advanced disease as well an cancer.To determine whether or gemcitabine superior terms overall survival adjuvant treatment following resection cancer.The European Study Group Pancreatic Cancer (ESPAC)-3 trial, open-label, phase 3, randomized controlled trial conducted 159 cancer centers Europe, Australasia, Japan, and Canada. Included ESPAC-3...
Purpose Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate is unknown. Patients Methods with ductal adenocarcinoma treated within international, phase III, European Study Group Pancreatic Cancer–3 (version 2) study were included if they had been randomly assigned chemotherapy. Overall analysis was performed on an intention-to-treat basis, retaining patients in their randomized groups, adjusting...
Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival patients who receive adjuvant gemcitabine after resection. Microarrays from 434 randomized to chemotherapy the ESPAC-3 trial (plus controls ESPAC-1/3) were stained with 10D7G2 anti-hENT1 antibody. Patients classified as having high hENT1 expression if mean H score for their cores was above overall median (48). High and low hENT1-expressing groups compared using Kaplan–Meier curves,...
Comparison of minimal access retroperitoneal pancreatic necrosectomy (MARPN) versus open in the treatment infected or nonresolving necrosis.Infected necrosis may lead to progressive organ failure and death. Minimal techniques have been developed an attempt reduce high mortality necrosectomy.This was a retrospective analysis on prospective data base comprising 189 consecutive patients undergoing MARPN (August 1997 September 2008). Outcome measures included total postoperative ICU hospital...
<h3>Importance</h3> Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Advances in next-generation sequencing provide a route to therapeutic approaches, and integrating DNA RNA analysis clinicopathologic data may be crucial step toward personalized treatment strategies this disease. <h3>Objective</h3> To classify PDAC according distinct mutational processes, explore their clinical significance. <h3>Design, Setting, Participants</h3> We performed retrospective...
<h3>Background and aims</h3> The role of GATA factors in cancer has gained increasing attention recently, but the function GATA6 pancreatic ductal adenocarcinoma (PDAC) is controversial. amplified a subset tumours was proposed to be oncogenic, high levels are found well-differentiated associated with better patient outcome. By contrast, tumour-suppressive demonstrated using genetic mouse models. We aimed at clarifying PDAC. <h3>Design</h3> combined silencing overexpression PDAC cell lines...
Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapies.
The patterns of disease recurrence after resection pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear.
4505 Background: Patients with borderline resectable pancreatic cancer have poor survival and low resection rates. Neoadjuvant therapy may improve the outcome for these patients. The aim of this trial was to determine feasibility efficacy a comparison immediate surgery versus neoadjuvant GEMCAP or FOLFIRINOX CRT. Methods: Eligible patients NCCN defined (following central review baseline CT scan) biopsy proven were randomised (stratified by centre) receive surgery, either 2 cycles GEMCAP, 4...
Abstract Pancreatic ductal adenocarcinoma is a highly metastatic disease and macrophages support liver metastases. Efferocytosis, or engulfment of apoptotic cells by macrophages, an essential process in tissue homeostasis wound healing, but its role metastasis less well understood. Here, we found that the colonization hepatic site accompanied low-grade injury efferocytosis-mediated clearance parenchymal dead promotes macrophage reprogramming metastasis. Mechanistically, progranulin...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease for which better therapies are urgently needed. Fibroblasts and macrophages heterogeneous cell populations able to enhance metastasis, but the role of macrophage-fibroblast crosstalk in regulating their pro-metastatic functions remains poorly understood. Here we deconvolve how regulate metastasis-associated fibroblast (MAF) heterogeneity liver. We identify three functionally distinct MAF populations, among...
Importance Patients undergoing unplanned abdominal surgical procedures are at increased risk of site infection (SSI). It is not known if incisional negative pressure wound therapy (iNPWT) can reduce SSI rates in this setting. Objective To evaluate the effectiveness iNPWT reducing rate adults emergency laparotomy with primary skin closure. Design, Setting, and Participants SUNRRISE was an assessor-masked, pragmatic, phase 3, individual-participant, randomized clinical trial. Adult patients 22...
Aims: The current Royal College of Pathologists guidelines for pancreatoduodenectomy specimen reporting recommend that microscopic evidence tumour within 1 mm a resection margin (RM) should be classified as R1. No clinical exists to justify this classification. aim study was identify the proportion specimens in which ‘equivocal’ RMs are present (tumour involvement of, but not directly reaching, one or more margins) and whether survival these patients similar with ‘unequivocal’ RM...